Piramal Pharma Limited Announces Consolidated Results for Q4 and FY2023

/PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), today announced its consolidated results for the fourth quarter (Q4) and full year FY23...

Related Keywords

Dahej ,Gujarat ,India ,Hong Kong ,United Kingdom ,Digwal ,Andhra Pradesh ,New York ,United States ,Ahmedabad ,Riverview ,Singapore ,London ,City Of ,Mumbai ,Maharashtra ,Grangemouth ,Falkirk ,Yapan Bio ,Nandini Piramal ,Piramal Pharma Solutions ,Carlyle Group ,Hemmo Pharmaceuticals Pvt Ltd ,Abbvie Inc ,Piramal Pharma ,Piramal Enterprises Ltd ,Convergence Chemical Pvt Ltd ,Manufacturing Organization ,Facebook ,Piramal Pharma Limited ,Contract Development ,Twitter ,Piramal Pharma Ltd ,Allergan India Private ,Prnewswire Piramal Pharma Limited ,Pharma Limited ,Inhalation Anesthesia ,India Consumer Healthcare ,Business Highlights ,Hospital Generics ,Pain Management ,Consumer Healthcare ,Lacto Calamine ,Establishment Inspection ,Forwarding Agent ,Deferred Tax Assets ,Primary Number ,Eastern Time ,London Time ,Singapore Time ,Hong Kong Time ,Piramal Critical Care ,Complex Hospital Generics ,Allergan India Private Limited ,